HPV VACCINATION RATES LOW DESPITE RISKS OF RELATED CANCERS

The Centers for Disease Control and Prevention’s (CDC) recent survey that assessed cervical cancer in the fourth most common cancers among women globally, with cervical cancer awareness campaigns. A recent study of vaccination rates among women and men, the HPV vaccine is recommended for 70-133% of those aged 16-26 years in the U.S. The vaccination rates correlate directly with less than 5% completion among children aged 10-13.

The states of the HPV vaccine are required for full immunity among the age group. While it is not required for school admission across the U.S. like many other vaccines, the HPV vaccine is easily accessible at annual wellness visits and is a critical step in fighting these preventable diseases. For those using an HPV vaccine on a population for a three-year period for the commercially insured.

Among children ages 10-13:

- Vaccination rates were aggregated by ZIP code for regional and race/ethnicity comparisons. Race/ethnicity is determined by ZIP code when less than 5% of the households identify as either Black, Hispanic or white.
- Source: BCBS Axis Data

### Why it matters

HPV is the most common sexually transmitted infection. However, HPV vaccination rates remain concerning among the 10-13 age group. By vaccinating our population ages 10-13, we are not only preventing viral infections, but also reducing the risk of future cancers later in life—many of which are or are becoming increasingly common.

- Cervical cancer is the fourth most common cancer among women globally, while certain throat cancer diagnoses1 are rising at unprecedented rates among men and women. HPV is responsible for 70-90% of these cancers among children aged 10-13.
- Two doses of the HPV vaccine are required for full immunity among this age group.3 While it is not required for school admission across the U.S. like many other vaccines, the HPV vaccine is easily accessible at annual wellness visits and is a critical step in fighting these preventable diseases.
- For those using an HPV vaccine on a population for a three-year period for the commercially insured.

### How can we improve HPV vaccination rates?

Leading HPV vaccination rates vary at these three completion rates, reinforcing the importance of adhering to prescribed well child visits.

- 2013-16 Cohort
- 2016-19 Cohort

**INITIATION RATES ARE GROWING MOST RAPIDLY AMONG MALES, WHILE GROWTH OF COMPLETION RATES IS HIGHER AMONG FEMALES**

<table>
<thead>
<tr>
<th>2013-16 Cohort</th>
<th>2016-19 Cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male (1st Dose)</td>
<td>Female (1st Dose)</td>
</tr>
<tr>
<td>54%</td>
<td>38%</td>
</tr>
<tr>
<td>Male (Completed)</td>
<td>Female (Completed)</td>
</tr>
<tr>
<td>46%</td>
<td>27%</td>
</tr>
</tbody>
</table>

- Why is this important? Vaccinations for children and adults of all ages. As with the COVID-19 vaccine, getting both doses of the HPV vaccine is critical for effective vaccination. These preventive measures help ensure the health and safety of our families and communities.

### Increasing access to preventive care, for the health of America.

Learn More

INCREASING ACCESS TO PREVENTIVE CARE, FOR THE HEALTH OF AMERICA.

www.healthofamerica.com

©2021 Blue Cross and Blue Shield Association. All rights reserved. Blue Cross Blue Shield Association is an association of independent Blue Cross and Blue Shield companies.